EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy

Weiman Huang, Rujie Shi, Yujing Wang, Xidi Wang, Zuodong Qin, Xiaofang Luo, Kun Li, Baisheng Wang, Yanjia Hu

Oral Diseases · 2026-11-10

DOI: 10.1111/odi.70569 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objectives To investigate the anti‐fibrotic effects and mechanism of action of the bioactive peptide HX‐12C in oral submucous fibrosis. Materials and Methods Primary human buccal mucosal fibroblasts were treated with arecoline to induce a myofibroblast phenotype. The effects of HX‐12C on cell proliferation, migration and fibrotic markers were assessed. Molecular docking and immunofluorescence were used to examine HX‐12C binding to transforming growth factor‐beta receptor I, validated by the inhibitor SB‐431542. In vivo efficacy was evaluated in a bleomycin‐induced rat model of oral submucous fibrosis. Results HX‐12C promoted fibroblast proliferation and migration but suppressed arecoline‐induced myofibroblast activation, downregulating alpha‐smooth muscle actin, fibronectin and collagens I/III. Mechanistically, HX‐12C bound to transforming growth factor‐beta receptor I, inhibited SMAD2/3 phosphorylation and downstream pro‐fibrotic gene expression, effects attenuated by SB‐431542. In vivo, HX‐12C improved mouth opening and reduced collagen deposition. Conclusions HX‐12C exerts potent anti‐fibrotic effects by directly targeting transforming growth factor‐beta receptor I and inhibiting the canonical transforming growth factor‐beta/Smad signalling pathway. Our findings identify HX‐12C as a promising therapeutic candidate for oral submucous fibrosis and provide a rationale for developing peptide‐based therapies for transforming growth factor‐beta‐driven fibrotic diseases.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →